查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1584715

活性药物成分市场：按类型、合成、製造商、治疗应用分类 - 全球预测 2025-2030

Active Pharmaceutical Ingredients Market by Type, Synthesis, Manufacturer, Therapeutic Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年活性药物成分市值为1527.7亿美元，预计2024年将达到1643.4亿美元，复合年增长率为7.88%，到2030年将达到2599.7亿美元。

活性药物成分 (API) 是药物的重要组成部分，可提供其预期效果。原料药的范围涵盖药物製剂的需求、疾病治疗的广泛应用以及製药、生物技术和契约製造组织的最终用途。慢性病新兴市场的扩大、老年人口的增加以及药物开发技术的进步是原料药市场的关键成长要素。生技药品的日益普及和特种药物需求的激增是值得注意的机会。专利到期、学名药增加以及对个人化医疗的关注等因素进一步推动市场发展。强调药物功效和安全性的监管要求正在推动製造流程的创新并创造机会，特别是在绿色化学和生物技术进步方面。

主要市场统计
基准年[2023] 1527.7亿美元
预测年份 [2024] 1643.4亿美元
预测年份 [2030] 2599.7亿美元
复合年增长率（%） 7.88%

然而，市场并非没有挑战。严格的法律规范、高製造成本和复杂的製造流程是主要障碍。原材料供应中断的威胁，特别是由于地缘政治紧张局势和对有限供应商的依赖，可能会阻碍市场成长。此外，每个地区的合规规范都在不断发展，需要不断调整，这可能会影响公司的业务效率。为了抓住新机会，企业应该投资开发永续和环保的製造工艺，利用人工智慧和机器学习来优化生产，并加强品管。对生物相似药和新型药物输送系统的追求提供了竞争优势。

原料药市场高度活跃，其特点是旨在扩大产品系列和推广范围的策略联盟和合併。对研究和开发的关注，特别是核酸和胜肽等非传统 API，代表了一个有前途的创新领域。虽然该行业是技术密集型行业，但它的繁荣也依赖对不断变化的法规和市场需求的适应，并且需要采取积极主动的风险管理和生产适应性方法以维持长期成长。

市场动态：快速发展的活性药物成分市场的关键市场洞察

供需的动态交互作用正在改变活性药物成分市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 製药公司活性化研发活动
    • 政府对先进医药製造技术的支持
    • CDMO增加投资以增强药品生产能力
  • 市场限制因素
    • 先进 API 技术带来的高成本
  • 市场机会
    • 活性药物成分技术的技术进步
    • 采用微粉化技术开发新治疗药物
  • 市场挑战
    • 实现和维持所需粒径分布涉及的技术复杂性

波特五力：驾驭活性药物成分市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解原料药市场的外部影响

外部宏观环境因素在塑造活性药物成分市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解药物活性成分市场的竞争状况

对活性药物成分市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵活性药物成分市场供应商的绩效评估

FPNV 定位矩阵是评估活性药物组成市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

战略分析与推荐活性药物成分市场成功图表

对于旨在加强在全球市场的影响力的公司来说，活性药物成分市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 製药公司研发活动增加
      • 政府对先进医药製造技术的支持
      • CDMO增加投资以增强药品生产能力
    • 抑制因素
      • 先进 API 技术带来的高成本
    • 机会
      • 活性药物成分技术的技术进步
      • 采用微粉化技术开发新药
    • 任务
      • 与实现和维持所需粒径分布相关的技术复杂性
  • 市场区隔分析
    • 类型：透过降低研发成本提高通用 API 的可访问性
    • 治疗应用：糖尿病的全球盛行率推动了活性药物成分的研究和开发
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章活性药物成分市场：依类型

  • 常见的活性药物成分
  • 创新活性药物成分

第七章活性药物成分市场：透过合成

  • 生物技术药物活性成分
  • 合成药物活性成分

第八章活性药物成分市场：依製造商分类

  • 专属式API 製造商
  • 商家 API 製造商

第九章活性药物成分市场：依治疗应用分类

  • 心血管疾病
  • 传染病
  • 糖尿病
  • 肿瘤学
  • 疼痛管理
  • 呼吸系统疾病

第十章美洲原料药市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太原料药市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲原料药市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 礼来公司 (Eli Lilly) 投资创纪录的 90 亿美元，以扩大糖尿病和减肥药的 API 生产
    • 美国合作促进密苏里州新肿瘤设施生产胶质神经胶母细胞瘤必需药物
    • Noramco 集团加强北美药品供应链
  • 战略分析和建议

公司名单

  • Abbvie Inc.
  • API Pharma Tech
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • BASF SE
  • BDR Pharmaceuticals Internationals Pvt. Ltd.
  • Bristol-Myers Squibb Company
  • CH Boehringer Sohn AG & Co. KG
  • Cipla, Inc.
  • Dr. Reddy's Laboratories Ltd
  • ELI Lilly and Company
  • F. Hoffmann-La Roche AG
  • Glaxosmithkline PLC
  • Lonza Group Ltd.
  • Lupin Ltd.
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer, Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd
  • Viatris Inc.
Product Code: MRR-430D42AA0F7B

The Active Pharmaceutical Ingredients Market was valued at USD 152.77 billion in 2023, expected to reach USD 164.34 billion in 2024, and is projected to grow at a CAGR of 7.88%, to USD 259.97 billion by 2030.

Active Pharmaceutical Ingredients (APIs) form the critical components in pharmaceuticals, responsible for the intended effects of drugs. The scope of APIs encompasses their necessity in drug formulation, wide-ranging applications across disease treatments, and end-use in pharmaceuticals, biotechnology, and contract manufacturing organizations. The growing prevalence of chronic diseases, increasing geriatric population, and advancements in drug development technologies are pivotal growth factors in the API market. The rising adoption of biologics and the surge in demand for specialty medicines present notable opportunities. Factors such as patent expirations, increased generic drug production, and a focus on personalized medicine further bolster market advancements. Regulatory mandates that stress drug efficacy and safety are driving innovations in manufacturing processes, fostering opportunities especially within green chemistry and biotechnological advancements.

KEY MARKET STATISTICS
Base Year [2023] USD 152.77 billion
Estimated Year [2024] USD 164.34 billion
Forecast Year [2030] USD 259.97 billion
CAGR (%) 7.88%

However, the market is not devoid of challenges. Stringent regulatory frameworks, high production costs, and complex manufacturing processes pose significant hurdles. The threat of raw material supply disruptions, particularly due to geopolitical tensions and dependency on a limited number of suppliers, can hinder market growth. Moreover, evolving compliance norms across regions necessitate constant adaptation, potentially impacting firms' operational efficiencies. To capitalize on emerging opportunities, companies should invest in the development of sustainable and eco-friendly manufacturing processes, leveraging AI and machine learning to optimize production and enhance quality control. Pursuing biosimilars and novel drug delivery systems can offer competitive advantages.

The API market is highly dynamic, characterized by strategic collaborations and mergers aimed at expanding product portfolios and geographical outreach. Emphasis on research and development, particularly in non-traditional APIs like nucleic acids and peptides, marks a promising area for innovation. While being technology-intensive, the industry also thrives on adaptability to regulatory changes and market demands, making it crucial for players to maintain a proactive approach in risk management and production adaptability to sustain long-term growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Active Pharmaceutical Ingredients Market

The Active Pharmaceutical Ingredients Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing research & development activities by pharmaceutical companies
    • Government support for advanced pharmaceutical manufacturing techniques
    • Rising investments to enhance drug manufacturing capabilities by CDMOs
  • Market Restraints
    • High cost associated with advanced API technologies
  • Market Opportunities
    • Technological advancements in active pharmaceutical ingredients techniques
    • Adoption of micronization techniques to develop novel drug therapeutics
  • Market Challenges
    • Technical complexity associated with achieving and maintaining the desired particle size distribution

Porter's Five Forces: A Strategic Tool for Navigating the Active Pharmaceutical Ingredients Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Active Pharmaceutical Ingredients Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Active Pharmaceutical Ingredients Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Active Pharmaceutical Ingredients Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Active Pharmaceutical Ingredients Market

A detailed market share analysis in the Active Pharmaceutical Ingredients Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Active Pharmaceutical Ingredients Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Active Pharmaceutical Ingredients Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Active Pharmaceutical Ingredients Market

A strategic analysis of the Active Pharmaceutical Ingredients Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Active Pharmaceutical Ingredients Market, highlighting leading vendors and their innovative profiles. These include Abbvie Inc., API Pharma Tech, AstraZeneca PLC, Aurobindo Pharma Limited, BASF SE, BDR Pharmaceuticals Internationals Pvt. Ltd., Bristol-Myers Squibb Company, C.H. Boehringer Sohn AG & Co. KG, Cipla, Inc., Dr. Reddy's Laboratories Ltd, ELI Lilly and Company, F. Hoffmann-La Roche AG, Glaxosmithkline PLC, Lonza Group Ltd., Lupin Ltd., Merck & Co., Inc., Novartis International AG, Pfizer, Inc., Sanofi S.A., Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Active Pharmaceutical Ingredients Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Generic Active Pharmaceutical Ingredients and Innovative Active Pharmaceutical Ingredients.
  • Based on Synthesis, market is studied across Biotech Active Pharmaceutical Ingredients and Synthetic Active Pharmaceutical Ingredients.
  • Based on Manufacturer, market is studied across Captive API Manufacturers and Merchant API Manufacturers.
  • Based on Therapeutic Application, market is studied across Cardiovascular Diseases, Communicable Diseases, Diabetes, Oncology, Pain Management, and Respiratory Diseases.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing research & development activities by pharmaceutical companies
      • 5.1.1.2. Government support for advanced pharmaceutical manufacturing techniques
      • 5.1.1.3. Rising investments to enhance drug manufacturing capabilities by CDMOs
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with advanced API technologies
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in active pharmaceutical ingredients techniques
      • 5.1.3.2. Adoption of micronization techniques to develop novel drug therapeutics
    • 5.1.4. Challenges
      • 5.1.4.1. Technical complexity associated with achieving and maintaining the desired particle size distribution
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Increasing accessibility of generic APIs due to eliminated R&D expenses
    • 5.2.2. Therapeutic Application: Increasing prevalence of diabetes globally boost the R&D for active pharmaceutical ingredients
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Active Pharmaceutical Ingredients Market, by Type

  • 6.1. Introduction
  • 6.2. Generic Active Pharmaceutical Ingredients
  • 6.3. Innovative Active Pharmaceutical Ingredients

7. Active Pharmaceutical Ingredients Market, by Synthesis

  • 7.1. Introduction
  • 7.2. Biotech Active Pharmaceutical Ingredients
  • 7.3. Synthetic Active Pharmaceutical Ingredients

8. Active Pharmaceutical Ingredients Market, by Manufacturer

  • 8.1. Introduction
  • 8.2. Captive API Manufacturers
  • 8.3. Merchant API Manufacturers

9. Active Pharmaceutical Ingredients Market, by Therapeutic Application

  • 9.1. Introduction
  • 9.2. Cardiovascular Diseases
  • 9.3. Communicable Diseases
  • 9.4. Diabetes
  • 9.5. Oncology
  • 9.6. Pain Management
  • 9.7. Respiratory Diseases

10. Americas Active Pharmaceutical Ingredients Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Active Pharmaceutical Ingredients Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Active Pharmaceutical Ingredients Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Eli Lilly's Record-Breaking USD 9 Billion Investment to Boost API Manufacturing for Diabetes and Obesity Treatments
    • 13.3.2. United States Collaboration Enhances Production of Essential Glioblastoma Drug with New Oncology Suite in Missouri
    • 13.3.3. Noramco Group Strengthening North America's Pharmaceutical Supply Chain
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbvie Inc.
  • 2. API Pharma Tech
  • 3. AstraZeneca PLC
  • 4. Aurobindo Pharma Limited
  • 5. BASF SE
  • 6. BDR Pharmaceuticals Internationals Pvt. Ltd.
  • 7. Bristol-Myers Squibb Company
  • 8. C.H. Boehringer Sohn AG & Co. KG
  • 9. Cipla, Inc.
  • 10. Dr. Reddy's Laboratories Ltd
  • 11. ELI Lilly and Company
  • 12. F. Hoffmann-La Roche AG
  • 13. Glaxosmithkline PLC
  • 14. Lonza Group Ltd.
  • 15. Lupin Ltd.
  • 16. Merck & Co., Inc.
  • 17. Novartis International AG
  • 18. Pfizer, Inc.
  • 19. Sanofi S.A.
  • 20. Sun Pharmaceutical Industries Ltd
  • 21. Teva Pharmaceutical Industries Ltd
  • 22. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. ACTIVE PHARMACEUTICAL INGREDIENTS MARKET RESEARCH PROCESS
  • FIGURE 2. ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ACTIVE PHARMACEUTICAL INGREDIENTS MARKET DYNAMICS
  • TABLE 7. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY CAPTIVE API MANUFACTURERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MERCHANT API MANUFACTURERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMMUNICABLE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 191. ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, FPNV POSITIONING MATRIX, 2023